Intranasal Drug Delivery Devices Market Size to Hit Around US$ 2.98 Billion by 2030
May 26, 2021 10:00 ET
|
Precedence Research
OTTAWA, May 26, 2021 (GLOBE NEWSWIRE) -- Precedence Research says, the global intranasal drug delivery devices market was valued at USD 1.17 billion in 2020. Drug delivery primarily refers to a...
CFN Media Interviews David Sutton of NanoSphere Health Sciences Inc.
May 22, 2018 08:40 ET
|
CFN Media
SEATTLE, May 22, 2018 (GLOBE NEWSWIRE) -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, today announced publication...
Hemispherx Human Safety Study of Intranasal Ampligen® with Influenza Vaccine Shows Ampligen was Generally Well-Tolerated
August 14, 2017 08:30 ET
|
LinkedIn
PHILADELPHIA, Aug. 14, 2017 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced that it has commenced full data analysis of an intranasal human safety study of Ampligen® plus FluMist®...
FDA Authorizes New Hemispherx Biopharma Clinical Trial of Intranasal Ampligen(R) With Seasonal Influenza Vaccine
July 20, 2011 08:00 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, July 20, 2011 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company" or "Hemispherx") today announced it has received U.S. Food Drug Administration (FDA)...